Home Physical Sciences Crystal structure of (E)-2-(4-fluoro-2-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
Article Open Access

Crystal structure of (E)-2-(4-fluoro-2-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2

  • Ming-Zhu Luan ORCID logo , Hui-Yun Wang , Mei Zhang , Jia Song , Yang-Rong Xu , Feng-Lan Zhao and Qing-Guo Meng EMAIL logo
Published/Copyright: November 2, 2020

Abstract

C19H14F4O2, monoclinic, C2/c (no. 15), a = 17.1519(13) Å, b = 13.9810(8) Å, c = 15.2299(9) Å, β = 123.031(7)°, V = 3061.9(4) Å3, Z = 8, Rgt(F) = 0.0410, wRref(F2) = 0.1010, T = 100(1) K.

CCDC no.: 2027098

The molecular structure is shown in the Figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.14 × 0.13 × 0.12 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.13 mm−1
Diffractometer, scan mode:SuperNova, ω
θmax, completeness:25.5°, >99%
N(hkl)measured, N(hkl)unique, Rint:7328, 2862, 0.027
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2364
N(param)refined:227
Programs:CrysAlisPRO [1], SHELX [2], [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.15858 (12)0.32258 (13)0.34683 (13)0.0216 (4)
C20.13311 (12)0.40869 (13)0.38473 (12)0.0216 (4)
C30.06355 (12)0.39118 (13)0.41445 (13)0.0244 (4)
H3A0.0026680.3795680.3518140.029*
H3B0.0593980.4473920.4490290.029*
C40.09287 (12)0.30525 (13)0.48741 (13)0.0252 (4)
H4A0.1515090.3187900.5523370.030*
H4B0.0465230.2930220.5038560.030*
C50.08278 (12)0.12699 (14)0.45434 (14)0.0271 (4)
H50.0638270.1190320.5006270.033*
C60.09002 (12)0.04824 (14)0.40523 (14)0.0275 (4)
H60.076345−0.0121500.4189540.033*
C70.11778 (11)0.05825 (13)0.33484 (13)0.0232 (4)
C80.14015 (11)0.14734 (13)0.31668 (13)0.0226 (4)
H80.1600900.1544480.2711970.027*
C90.13271 (11)0.22752 (13)0.36722 (12)0.0211 (4)
C100.10321 (12)0.21842 (13)0.43627 (13)0.0226 (4)
C110.17173 (12)0.49206 (13)0.38675 (13)0.0234 (4)
H110.2113790.4918600.3628460.028*
C120.15803 (11)0.58469 (13)0.42303 (13)0.0224 (4)
C130.13661 (11)0.66879 (13)0.36431 (13)0.0217 (4)
C140.12213 (11)0.75452 (14)0.39928 (13)0.0239 (4)
H140.1078280.8102130.3599570.029*
C150.12959 (12)0.75459 (13)0.49395 (14)0.0243 (4)
C160.15281 (12)0.67566 (14)0.55613 (14)0.0270 (4)
H160.1587280.6786640.6205050.032*
C170.16721 (12)0.59111 (14)0.52000 (13)0.0248 (4)
H170.1835640.5366380.5614940.030*
C180.12763 (12)0.66818 (13)0.26046 (14)0.0251 (4)
C190.15224 (14)−0.01821 (14)0.21971 (15)0.0314 (5)
H19A0.1109120.0219320.1612850.047*
H19B0.153713−0.0808840.1948880.047*
H19C0.2136320.0087560.2566360.047*
F10.11301 (8)0.83847 (8)0.52698 (8)0.0353 (3)
F20.06892 (7)0.60081 (8)0.19533 (8)0.0320 (3)
F30.20967 (7)0.65053 (8)0.27124 (8)0.0339 (3)
F40.09746 (8)0.75128 (8)0.20967 (8)0.0329 (3)
O10.19860 (9)0.33000 (9)0.30076 (10)0.0296 (3)
O20.12024 (9)−0.02482 (9)0.28854 (10)0.0289 (3)

Source of material

7-Methoxy-3,4-dihydronaphthalen-1(2H)-one and 4-fluoro-2-(trifluoromethyl)benzaldehyde were dissolved in 10 mL of methanol. After the addition of 5 mL 25% NaOH solution, the mixture was stirred for 3 h at ambient temperature (monitored by TLC, 254 nm). The mixture was filtered and subsequently dissolved with ethyl acetate, and the organic phase was washed with water and brine, and finally dried over anhydrous sodium sulfate. After filtration, the filtrate was evaporated to dryness under vacuum and purified on a silica gel by column chromatography using petroleum ether/EtOAc (2:1, v/v) as the eluent. The title compound was recrystallized from dichloromethane and methanol (1:1, v/v) to attain suitable crystals.

Experimental details

The H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C–H) = 0.97 Å (methylene), Uiso(H) = 1.2 Ueq(C), d(C–H) = 0.93 Å (aromatic), Uiso(H) = 1.2 Ueq(C), and d(C–H) = 0.96 Å (methyl), Uiso(H) = 1.5 Ueq(C).

Comment

Microglial cells function as the immune cells of the central nervous system (CNS), acting as primary mediators of inflammation. Neuroinflammation in the CNS mediated by overactivated microglia plays a key role in many neurodegenerative diseases [4], [5], [6]. M1 type microglial activation leads to proinflammatory effects by producing numerous cyto-mediators, such as proteases, proinflammatory cytokines and reactive oxygen species (ROS) [7]. Studies have shown that the inhibition of NF-κB signal pathway in microglia can reduce the expression of pro-inflammatory cytokines such as nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6, and play an anti-neuroinflammatory effect [8], [9], [10], [11]. Therefore, developing an NF-κB inhibitor with anti-neuroinflammatory activities and low toxicity is a potential therapeutic strategy for treating inflammatory neurodegenerative CNS diseases [12].

3,4–Dihydronaphthalen-1(2H)-one (DHN) derivatives with anti-inflammatory activities have been investigated as potential Bcl-2 inhibitors and as anti-inflammatory agents that stabilize mast cells [13], [14], [15]. However, DHN derivatives have rarely been developed as anti-neuroinflammatory drugs. Therefore, our group designed and synthesized a new benzylidene-substituted DHN derivative which may have anti-neuroinflammatory activity. The synthesis succeeded by a Claisen–Schmidt condensation reaction.

Single-crystal structure analysis revealed that the title compound crystallized in the monoclinic space group C2/c. The ORTEP diagram is presented in Figure. Bond lengths and angles are all in the expected ranges [16]. There is one drug molecule in the asymmetric unit (see the Figure). According to the configuration at the C(2) = C(11) olefinic bond, the title molecule adopts the E stereochemistry [17]. Because of the distorting effect of 3,4-dihydronaphthalen-1(2H)-one, the 7-methoxyphenyl and 4-fluoro-2-(trifluoromethyl)phenyl groups are not coplanar with each other, with a dihedral angle of 29.37(3)°. This twist may increase the likelihood of interactions with bio molecules with the aim of creating more potent anti-neuroinflammatory activity [18].


Corresponding author: Qing-Guo Meng, School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, P. R. China, E-mail:

Funding source: Science and Technology Innovation Development Plan of Yantai

Award Identifier / Grant number: 2020XDRH105

Award Identifier / Grant number: 81473104

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by Science and Technology Innovation Development Plan of Yantai (No. 2020XDRH105) and the National Natural Science Foundation of China (No. 81473104).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Rigaku, OD. CrysAlisPRO; Rigaku Oxford Diffraction Ltd: Yarnton, Oxfordshire, England, 2017.Search in Google Scholar

2. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122. https://doi.org/10.1107/s0108767307043930.Search in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8. https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Hong, Z. Y., Shi, X. R., Zhu, K., Wu, T. T., Zhu, Y. Z. SCM-198 inhibits microglial overactivation and attenuates Aβ1–40-induced cognitive impairments in rats via JNK and NF-κB pathways. J. Neuroinflamm. 2014, 11, 147. https://doi.org/10.1186/s12974-014-0147-x.Search in Google Scholar

5. Lee, D. S., Kwon, K. H., Cheong, S. H. Taurine chloramine suppresses LPS-induced neuroinflammatory responses through Nrf2-mediated heme oxygenase-1 expression in mouse BV2 microglial cells. Adv. Exp. Med. Biol. 2017, 975, 131–143. https://doi.org/10.1007/978-94-024-1079-2_12.Search in Google Scholar

6. Gao, C. L., Hou, G. G., Liu, J., Ru, T., Xu, Y. Z., Zhao, S. Y., Ye, H., Zhang, L. Y., Chen, K. X., Guo, Y. W., Pang, T., Li, X. W. Synthesis and target identification of benzoxepane derivatives as potential anti-neuroinflammatory agents for ischemic stroke. Angew. Chem. Int. Ed. 2020, 59, 2429–2439. https://doi.org/10.1002/anie.201912489.Search in Google Scholar

7. Su, P., Zhang, J., Wang, D., Zhao, F., Cao, Z., Aschner, M., Luo, W. The role of autophagy in modulation of neuroinflammation in microglia. Neuroscience 2016, 319, 155–167. https://doi.org/10.1016/j.neuroscience.2016.01.035.Search in Google Scholar

8. Cho, K. H., Kim, D. C., Yoon, C. S., Ko, W. M., Lee, S. J., Sohn, J. H., Jang, J. H., Ahn, J. S., Kim, Y. C., Oh, H. Anti-neuroinflammatory effects of citreohybridonol involving TLR4–MyD88-mediated inhibition of NF-κB and MAPK signaling pathways in lipopolysaccharide-stimulated BV2 cells. Neurochem. Int. 2016, 95, 55–62. https://doi.org/10.1016/j.neuint.2015.12.010.Search in Google Scholar

9. Zhang, J. Q., Zhang, Q., Xu, Y. R., Li, H. X., Zhao, F. L., Wang, C. M., Liu, Z., Liu, P., Liu, Y. N., Meng, Q. G., Zhao, F. Synthesis and in vitro anti-inflammatory activity of C20 epimeric ocotillol-type triterpenes and protopanaxadiol. Planta Med. 2019, 85, 292–301. https://doi.org/10.1055/a-0770-0994.Search in Google Scholar

10. Wang, C. M., Liu, J., Deng, J. Q., Wang, J. Z., Weng, W. Z., Chu, H. X., Meng, Q. G. Advances in the chemistry, pharmacological diversity, and metabolism of 20(R)-ginseng saponins. J. Ginseng Res. 2020, 44, 14–23. https://doi.org/10.1016/j.jgr.2019.01.005.Search in Google Scholar

11. Liu, J., Xu, Y. R., Yang, J. J., Wang, W. Z., Zhang, J. Q., Zhang, R. Z., Meng, Q. G. Discovery, semisynthesis, biological activities, and metabolism of ocotillol-type saponins. J. Ginseng Res. 2017, 41, 373–378. https://doi.org/10.1016/j.jgr.2017.01.001.Search in Google Scholar

12. Srinivasan, M., Lahiri, D. K. Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis. Expert Opin. Ther. Targets 2015, 19, 471–487. https://doi.org/10.1517/14728222.2014.989834.Search in Google Scholar

13. Wang, F. L., Zhang, R. X., Cui, Y., Sheng, L. P., Sun, Y. P., Tian, W., Liu, X., Liang, S. Z. Design, synthesis and biological evaluation of 3,4-dihydronaphthalen-1(2H)-one derivatives as Bcl-2 inhibitors. Res. Chem. Intermed. 2017, 43, 5933–5942. https://doi.org/10.1007/s11164-017-2972-x.Search in Google Scholar

14. Barlow, J. W., Walsh, J. J. Synthesis and evaluation of 4-amino-3,4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds. Eur. J. Med. Chem. 2008, 43, 2891–2900. https://doi.org/10.1016/j.ejmech.2008.02.009.Search in Google Scholar

15. Sun, Y., Zhou, Y. Q., Liu, Y. K., Zhang, H. Q., Hou, G. G., Meng, Q. G., Hou, Y. Potential anti-neuroinflammatory NF-κB inhibitors based on 3,4-dihydronaphthalen-1(2H)-one derivatives. J. Enzym. Inhib. Med. Chem. 2020, 35, 1631–1640. https://doi.org/10.1080/14756366.2020.1804899.Search in Google Scholar

16. El-Sayed, N. E., Almaneai, N. M., Ghabbour, H. A., Alafeefy, A. M. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H18O4. Z. Kristallogr. N. Cryst. Struct. 2017, 232, 203–205.10.1515/ncrs-2016-0195Search in Google Scholar

17. Yao, B. R., Sun, Y., Chen, S. L., Suo, H. D., Zhang, Y. L., Wei, H., Wang, C. H., Zhao, F., Cong, W., Xin, W. Y., Hou, G. G. Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation. Eur. J. Med. Chem. 2019, 167, 187–199. https://doi.org/10.1016/j.ejmech.2019.02.020.Search in Google Scholar

18. Li, N., Yao, B. Y., Wang, C. H., Meng, Q. G., Hou, G. G. Synthesis, crystal structure and activity evaluation of novel 3,4-dihydro-1-benzoxepin-5(2H)-one derivatives as protein-tyrosine kinase (PTK) inhibitors. Acta Crystallogr. 2017, C73, 1003–1009. https://doi.org/10.1107/s2053229617015145.Search in Google Scholar

Received: 2020-09-20
Accepted: 2020-10-13
Published Online: 2020-11-02
Published in Print: 2021-01-26

© 2020 Ming-Zhu Luan et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of 3-oxo-urs-12-en-28-oic acid, C30H46O3·1/6H2O
  4. The crystal structure of (3S,12R,20R,24R)-3,12-diacetyl-20,24-epoxy-dammarane-3,12,25–triol–ethyl acetate (4/1), C34H56O6⋅ 0.25(C4H8O2)
  5. A new polymorph of tetrakis(dimethylammonium) catena-poly[tetrakis(μ2-sulfato-κ2O:O′)dizinc(II)], Zn2C8H32N4O16S4
  6. Crystal structure of 10-oxysophoridine, C15H22N2O2
  7. The crystal structure of (5R,8R,9R,10R,12R,13R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)tetradecahydro-3H-cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O4
  8. Synthesis, crystal structure and optical property of 1,6-bis(p-tolylthio)pyrene, C30H22S2
  9. The crystal structure of hexakis(2-(pyridin-2-ylamino)pyridin-1-ium) decavanadate(V) dihydrate, C60H64N18O30V10
  10. Preparation and crystal structure of a cationic olefin polymerization precatalyst: (1,7-bis(2,6–dichlorophenyl)-1,7-di-aza-4-oxo-heptan-1,4,7-triyl)dimethyl zirconium(IV), C18H20Cl4N2OZr
  11. The crystal structure of fac-tricarbonyl(4,4-dimethyl-2,2-dipyridyl-κ2N,N′)- (pyrazole-κN)rhenium(I) nitrate, C18H16O3N4Re
  12. Synthesis and crystal structure of hexaaquacopper(II) 2,5-dicarboxyterephthalate, C10H16O14Cu
  13. The crystal structure of (8R,10R,12R,14R)- 12-hydroxy-16-(5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)- 4,4,8,10,14-pentamethyltetradecahydro-3H- cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O5
  14. Structure of the mixed crystal (S)-(6-(bromo/chloro)-2-methoxy-2,6-dihydroquinolin-3-yl)(phenyl)methanol, C17H14Br0.5Cl0.5NO2
  15. The crystal structure of trans-tetraaqua-bis(4-acetylphenoxyacetato-κ1O)manganese(II), C20H26O12Mn
  16. Crystal structure of (E)-2-(4-fluoro-3-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  17. Crystal structure of DL-α-(methylaminomethyl)benzyl alcohol, C9H13NO
  18. The crystal structure of dipentaerthritol hexanitrate, C10H16N6O19
  19. Crystal structure of N,N-diphenylformamide, C13H11NO
  20. Crystal structure of (E)-2-(3,5-bis(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen- 1(2H)-one, C20H14F6O2
  21. Crystal structure of ortho-methoxy benzaldehyde, C8H8O2 – a second polymorph and deposition of 3D coordinates
  22. Crystal structure of catena-poly[diaqua-bis(μ2-2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O:O')-(2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O,O')yttrium(III)], C51H79O11Y
  23. Crystal structure of benzylthiouronium chloride, C8H11ClN2S
  24. Synthesis and crystal structure of tert-butyl (2′R,3R,3′R,4aR,9aS)-1-acetyl-5-chloro-3″-methyl-2,5″,9′-trioxo-1″-phenyl-1″,4a′,5″,9a′-tetrahydro-1′H,3′H,9′H-dispiro[indoline-3,4′-xanthene-2′,4″-pyrazole]-3′-carboxylate, C36H32ClN3O7
  25. Crystal structure of 2-hydroxy-4-methoxy benzaldehyde, C8H8O3
  26. Crystal structure of poly[diaqua-(m3-3′,5′-dicarboxy-[1,1′-biphenyl]-3,4-dicarboxylato-K4O,O′:O″:O‴) cadmium(II)], C16H11O10Cd
  27. Crystal structure of {tetraaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)}-{triaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)} – water – acetone (1/1/8/2)
  28. Synthesis and crystal structure of bis{2-bromo-6-((E)-((4-((E)-1-(methoxy-imino)ethyl)phenyl)imino)methyl)phenolato- κ2N,O}zinc(II)-methanol(1/2), C65H60Br4N8O9Zn2
  29. Crystal structure of benzenesulphonic acid
  30. Crystal structure of N-benzyl-N-nicotinoyl-nicotine amide C19H15N3O2
  31. Crystal structure of poly[aqua(μ3-2,4-diamino-benzenesulfonato-κ4N:N′,O:O′)silver(I)], C12H18O8N4S2Ag2
  32. Crystal structure of 1,4-bis(methylpyridinium benzene) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C26H18N6NiS4
  33. Crystal structure of the Cu(II) complex chlorido-(6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxylato-k2N,O)-(phenanthroline-k2N,N')copper(II), C23H15ClCuN4O3
  34. Crystal structure of phenarsazine chloride acetic acid solvate, C14H13AsClNO2
  35. Crystal structure of poly[aqua-(μ2-3,3′,4,5′-biphenyl tetracarboxylate- κ3O,O′:O′′) -(μ2-4,4′-bis(pyrid-4-yl)biphenyl-κ2N:N′)zinc(II)], C27H18NO9Zn
  36. Crystal structure of catena-poly[(μ2-3-amino-benzenedisulfonato-κ2N:O)-bis (3-methyl-isoquinoline-κN)silver(I)], C26H24N3O3SAg
  37. Crystal structure of 2-((4-Aminophenyl)thio)acetic acid, C8H9NO2S
  38. Crystal structure of phenarsazine chloride dimethylsulfoxide solvate, C14H15AsClNOS
  39. Synthesis and crystal structure of 2-azido-N-phenylacetamide, C8H8N4O
  40. Crystal structure of chlorido{hydridotris[3-phenyl-5-methylpyrazol-1-yl-κN3]borato}copper(II), C30H28BClCuN6
  41. Crystal structure of benzanthrone – a redetermination for correct molecular geometry and localization of hydrogen atoms
  42. Crystal structure of 4-bromobenzaldehyde – complete redetermination at 200 K, C7H5BrO
  43. Crystal structure and spectroscopic properties of chlorido{hydridotris[3-,5-dimethylpyrazol-1-yl-κN3]borato}(3-,5-dimethylpyrazol-1-yl-κN)copper(II), C20H30BClCuN8
  44. The crystal structure of 4-((2-hydroxynaphthalen-1-yl)(pyrrolidin-1-yl)methyl)benzonitrile, C22H20N2O
  45. Crystal structure of 4-ethyl-3-phenylisoquinolin-1(2H)-one, C17H15NO
  46. Crystal structure of (tricyclohexylphosphane-κP)-[(Z)-N-(3-fluorophenyl)-O-methylthiocarbamato-k1S]gold(I), C26H40AuFNOPS
  47. Crystal structure of (3S,8R,10R,12R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl) hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate, C32H54O4
  48. The crystal structure of 2-[(S)-1-(naphthalen-1-yl)ethyl]-2,3,7,7a- tetrahydro-3a,6-epoxyisoindol-1(6H)-one, C19H20NO2
  49. Crystal structure of {hydridotris[3-(t-butyl)-5-isopropylpyrazol-1-yl-κN3]borato}thallium(I), C30H52BN6Tl
  50. Synthesis and crystal structure of 1-octyl-3-phenylquinoxalin-2(1H)-one, C22H26N2O
  51. The crystal structure of 2,6-difluorophenol, C6H4F2O
  52. 4-(9H-Fluoren-9-yl)-4-methylmorpholin-4-ium bromide, C18H20BrNO
  53. The crystal structure of 2,4-dimethylimidazole monohydrate, C5H10N2O
  54. The crystal structure of 1,2-dimethylimidazole, C5H8N2
  55. The crystal structure of 3-ammonio-4-aminobenzoate, C7H8N2O2 – a second polymorph
  56. The crystal structure of 4-hydroxy-2,5-bis(1-methyl-1H-imidazol-3-ium-2-ylthio)-3,6-dioxocyclohexa-1,4-dienolate chloride monohydrate, C14H15N4O5S2Cl
  57. The crystal structure of butyrylferrocene, C14H16FeO
  58. The crystal structure of bi-1,1′-cyclopentane-1,1′-diol, C10H18O2
  59. The crystal structure of 2-iso-propylimidazole, C6H10N2
  60. The crystal structure of aqua-tris (1,3-diphenylpropane-1,3-dionato-κ2O,O′)-lanthanum(III), C45H35LaO7
  61. Crystal structure of (3E,5E)-3,5-bis-4-methoxy-3-(trifluoromethyl)benzylidene)-1-methylpiperidin-4-one, C24H21F6NO3
  62. The crystal structure of 3,5-dichloro-6-diazo-2,4-dinitrocyclohexa-2,4-dien-1-one, C6Cl2N4O5
  63. Crystal structure of carbonyl(2-methylquinolin-8-olato-κ2N,O)(triphenylarsine-κAs)rhodium(I), C29H23AsNO2Rh
  64. Crystal structure of (1aS,1a1S,2S)-4a-butoxy-1a,1a1,2,4a,5,6-hexahydro-1H-cyclobuta[de]naphthalen-2-yl-4-nitrobenzoate, C22H25NO5
  65. Crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-k2O,O′)(triphenylarsine-κAs)rhodium(I), C24H19AsNO3Rh
  66. Crystal structure of catena-poly[triqua-bis(μ2-4-carboxy-2-(1H-tetrazol-1-yl)-1H-imidazole-5-carboxylato-k3N,O:O′)barium(II)] tetrahydrate, C14H14BaN12O15
  67. Crystal structure of (E)-3′,6′-bis(ethylamino)-2-((quinoxalin-2-ylmethylene)amino)spiro[isoindoline-1,9′-xanthen]-3-one, C35H32N6O2
  68. Crystal structure of diaqua-bis(μ2-5-chloro-salicylato-κ3O,O′:O′)-bis(5-chloro-salicylato-κ2O,O′)-bis(1,10-phenanthroline-κ2N,N′) dilead(II) – water (1/2), C52H36C14N4O14Pb2·2(H2O)
  69. Crystal structure of (E)-2-(4-ethoxycarbonyl-3,5-dimethyl-2-(pyrrole-2-ylmethyleneamino)-3′,6′-dihydroxylspiro[isoindoline-1,9′-xanthen]-3-one-methanol (1/1), C31H29N3O7
  70. The crystal structure of 5H-dibenzo[b,e]azepine-6,11-dione, C14H9NO2
  71. Crystal structure of (E)-2-(4-fluoro-2-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  72. The crystal structure of N-(2-methoxy-4,5-bis[phenylselanyl]phenyl)picolinamide, C25H20N2O2Se2
  73. The crystal structure of (E)-2-(5-bromo-2-hydroxybenzylidene)-N-phenylhydrazine-1- carboxamide monohydrate, C14H14BrN3O3
  74. Crystal structure of fac-tricarbonyl-(nitrato-k1O)-bis(pyridine-κN)-rhenium, C13H10O6N3Re
  75. Crystal structure of (E)-2-(((1H-pyrrol-2-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one — methanol (1/2), C27H25N3O6
  76. The crystal structure of 4-amino-N′-(4-aminobenzoyl)benzohydrazide monohydrate, C14H16N4O3
  77. Crystal structure of bis(amino(carbamothioylamino)methaniminium) 5-hydroxyisophthalate monohydrate, C12H20N8O6S2
  78. The crystal structure of 2-(chloromethyl)pyridine, C6H6ClN
  79. The crystal structure of 1-bromo-4-iodo-benzene, C6H4BrI
  80. The crystal structure of 2,6-dimethyl-4-nitro-phenol, C8H9NO3
  81. The crystal structure of 3-chloropropionic acid, C3H5ClO2
  82. The crystal structure of 2-(2-methoxyphenyl)acetic acid, C9H10O3
Downloaded on 25.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0484/html?srsltid=AfmBOopok5xzCuixiM7THJr4ApO8zGHusFCJCWkPRsMRAFStTc-TrH5f
Scroll to top button